We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Data from the ongoing Phase...
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in...
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster...
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced...
Galapagos receives transparency notification from EcoR1 Capital Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a...
Galapagos receives transparency notification from EcoR1 Capital Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a...
Galapagos receives transparency notification from FMR LLC Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency...
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Mechelen, Belgium; August 23, 2024, 07:00...
Galapagos receives transparency notification from FMR LLC Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency...
Galapagos reports half-year 2024 financial results and provides second quarter business update Executing on our Forward, Faster strategy with strong progress in a pivotal year, focused on...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.72 | 2.85487708168 | 25.22 | 25.92 | 24.92 | 11787 | 25.52650457 | DE |
4 | -0.22 | -0.840978593272 | 26.16 | 26.86 | 24.92 | 6701 | 25.6939471 | DE |
12 | -0.54 | -2.03927492447 | 26.48 | 28.78 | 23.68 | 7648 | 25.28493242 | DE |
26 | 1.74 | 7.19008264463 | 24.2 | 28.78 | 21.8 | 9225 | 24.99663401 | DE |
52 | -10.289999 | -28.4018749214 | 36.229999 | 38.9 | 21.8 | 8597 | 26.6520551 | DE |
156 | -23.235 | -47.2496187087 | 49.175 | 66.4 | 21.8 | 4329 | 27.48663039 | DE |
260 | -153.01 | -85.5043308187 | 178.95 | 189.3 | 21.8 | 2649 | 28.68205858 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions